Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet they can induce immune-related adverse events (irAEs), including cutaneous toxicities such as lichenoid eruptions. Pembrolizumab, a PD-1 inhibitor, is known for its association with lichen-planus-like reactions,...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Llyfr |
| Cyhoeddwyd: |
Frontiers Media S.A.,
2024-08-01T00:00:00Z.
|
| Pynciau: | |
| Mynediad Ar-lein: | Connect to this object online. |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
| Rhif Galw: |
A1234.567 |
|---|---|
| Copi 1 | Ar gael |